Fig. 4.

Application of a Piezo1 agonist suppresses the differentiation of brown adipocytes. A Representative images of Oil Red O staining of differentiated brown adipocytes treated with 1–30 μM Yoda-1 from days 0 to 8. Control denotes brown adipocytes in differentiation medium without the solvent. Vehicle denotes brown adipocytes in differentiation medium with solvent (0.1% DMSO). Scale bar: 100 μm. B The triglyceride levels in differentiated brown adipocytes treated with or without 1–30 μM Yoda-1 from days 0 to 8 (during induction and differentiation). The triglyceride levels were normalized to that in the vehicle treatment (absorbance; 0.280 ± 0.019). C The triglyceride levels in differentiated brown adipocytes treated with or without 1–30 μM Yoda-1 from days 2 to 8 (during differentiation). The triglyceride levels were normalized to that in the vehicle treatment (absorbance; 0.428 ± 0.029). D The changes in the mRNA levels of peroxisome proliferator-activated receptor γ (Pparγ, left), Pparγ coactivator1 α (Pgc1α, middle), and PRD1-BF1-RIZ1 homologous domain containing protein 16 (Prdm16, right) after 10 and 30 μM Yoda-1 treatment in differentiated brown adipocytes. Each expression level was normalized to that of 36b4. Each column represents the mean + SEM of 5–7 experiments. Statistical significance was assessed using ANOVA followed by two-tailed multiple t-tests with Bonferroni correction. *p < 0.05, **p < 0.01 vs. Vehicle. ^#p < 0.05, ^##p < 0.01, vs. Control